POASNYSEIndustrial Instruments For Measurement, Display, and ControlUS GAAP · USD

Phaos Technology Holdings (Cayman) Limited

PHAOS TECHNOLOGY HOLDINGS (CAYMAN) Ltd is a Cayman Islands holding company with operating headquarters in Singapore. Through its subsidiaries, it develops and sells advanced microscopy solutions used for high-precision imaging and measurement applications.

Liikevaihto0,1milj. USD
−21,2 %v/v
Liikevoitto (EBIT)−6,2milj. USD
−17,7 %v/v
EBIT-marginaali−4 706,8%
−1 558,5 %-yks.v/v
Nettotulos−6,2milj. USD
−19,9 %v/v
Vapaa kassavirta−10,9milj. USD
−181,0 %v/v

Tilikausi 2026 · muutos edellisvuodesta

Kehitys 2024–2026

−8−6−4−202milj. USD2024: 1,9 milj. USD2024: EBIT −2,5 milj. USD20242025: 0,17 milj. USD2025: EBIT −5,3 milj. USD20252026: 0,13 milj. USD2026: EBIT −6,2 milj. USD20260,13−6,2
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Microscopy systems55 %

High-precision microscopy instruments for imaging and analysis.

Imaging software and workflows20 %

Software used to capture, process, and analyze microscopy data.

Measurement and inspection solutions15 %

Instrument-based solutions for dimensional and visual inspection tasks.

Service and support10 %

Installation, maintenance, training, and technical support for customers.

Asiakkaat

The company sells microscopy solutions to organizations that need precise imaging, measurement, and inspection capability. Its buyers are typically research, laboratory, and industrial users that value resolution, repeatability, and application support. Demand is tied to customers that use microscopy in scientific, quality-control, or advanced inspection workflows.

Research and academic users

Buy microscopy platforms for scientific imaging, experimentation, and publication-grade analysis.

Industrial inspection customers

Buy instruments for quality control, failure analysis, and precision measurement.

Laboratory and technical facilities

Buy systems and software for routine imaging and measurement workflows.

Channel and institutional buyers

Buy through institutional purchasing processes or local sales partners for deployment support.

Strategia

The company’s priorities appear centered on building a focused advanced microscopy platform, supporting customers through specialized products and services, and maintaining governance and disclosure standards expected of a U.S.-listed foreign issuer. Its equity incentive plan suggests an emphasis on retaining technical and managerial talent in a specialized instrumentation business. The available reports do not provide a detailed operating roadmap or regional expansion plan.

Expand the microscopy product platformKeskipitkä aikaväli

A specialized instrumentation business depends on differentiated performance and application fit.

Retain technical talentLyhyt aikaväli

Product development and customer support depend on specialized personnel.

Maintain governance and reporting qualityLyhyt aikaväli

U.S. listing and foreign-issuer status require consistent disclosure and controls.

Maantiede

The company is headquartered in Singapore and organized as a Cayman Islands holding company, giving it an international corporate structure with operating presence in Asia. Public filings identify Singapore as the principal executive location, while its securities trade in the United States on NYSE American. The available reports do not disclose a formal revenue-by-country split.

Riskit

The business depends on specialized product demand, technical differentiation, and effective execution in a niche instrumentation market. Public filings also highlight governance and audit-related matters, which are especially important for a foreign private issuer with a U.S. listing. Like other industrial instrument makers, it faces risks from customer concentration, product acceptance, and the need to keep pace with technology requirements.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Dependence on specialized microscopy demand1Product and technology obsolescence2Audit and internal control risk3Governance and related-party scrutiny4
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Dependence on specialized microscopy demandVaikutus: KorkeaTodennäköisyys: Kohtalainen

    A narrow product set can make revenue sensitive to customer buying cycles and adoption rates.

    Kohdistuu: Advanced microscopy and inspection customers

  2. Product and technology obsolescenceVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Instrument makers must keep pace with imaging performance and workflow needs.

    Kohdistuu: Microscopy platforms and software

  3. Audit and internal control riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Auditor changes and prior going-concern language can raise questions about reporting robustness.

    Kohdistuu: Financial reporting and controls

  4. Governance and related-party scrutinyVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Foreign issuers face heightened investor and regulatory attention on control and disclosure matters.

    Kohdistuu: Corporate governance and related-party relationships

Kysy Clarifolta: Phaos Technology Holdings (Cayman) Limited

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition

Microscopy systems may include equipment, software, installation, and support elements with different timing.

Vaikutus: Can shift revenue between delivery dates and service periods.

Warranty and service provisions

Instrument businesses often need estimates for post-sale obligations and repairs.

Vaikutus: Affects gross margin and liability balances.

Equity compensation

The 2026 equity incentive plan creates share-based compensation expense.

Vaikutus: Impacts operating expenses and diluted share count.

Going-concern assessment

Prior auditor language referenced going-concern uncertainty in the historical financial statements.

Vaikutus: Can influence disclosures, valuation, and investor perception.

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Päivitetty: 28.9.2026